Prevalence of and risk factors for enlarged perivascular spaces in adult patients with moyamoya disease

BMC Neurology

Table 1 Clinical characteristics of the moyamoya disease and control groups

	Moyamoya disease group	Control group	p value
n, patients (hemisphere)	50 (100)	50 (100)
Age, median (IQR), y	41.5 (31.0-51.0)	40.5 (33.8-50.3)	0.629
Sex, male/female	14/36	14/36	1.000
Total number of EPVS, median (IQR)	43.8 (26.0-52.9)	23.8 (15.1-33.0)	<0.001
EPVS Grade, median (IQR)	4.0 (3.0-4.0)	3.0 (2.0-3.0)	<0.001
Grade 0/1/2/3/4, n	0/2/12/33/53	0/8/30/44/18
Interobserver discrepancy, n, median (IQR)	13, 0.0 (0.0-0.0)	25, 0.0 (0.0-0.8)
Hypertension, presence/absence	18/32	9/41	0.043
Diabetes mellitus, presence/absence	1/49	1/49	1.000
Hyperlipidemia, presence/absence	8/42	7/43	0.779
Stroke lesions (total), presence/absence	32/68	6/94	<0.001
Lacnar stroke, presence/absence	15/84	4/96	0.008
Large ischemic stroke, presence/absence	13/88	0/100	<0.001
Hemorrhagic stroke, presence/absence	4/96	2/98	0.683
Microbleeds, presence/absence	15/83	4/96	0.007
White matter lesions, presence/absence	57/43	34/66	0.001
Disease subtype	Ischemic stroke: 10	Cerebral aneurysm: 17
	TIA: 15	Migraine: 4
	Hemorrhagic stroke: 6	Cerebral hemorrhage: 2
	Epilepsy: 2	Brain AVM: 5
	Other: 17	Epilepsy: 5
		Brain tumor: 7
		Other: 10

IQR interquartile range, TIA transient ischemic attack, AVM arteriovenous malformation

ISSN: 1471-2377